NCT01900717View on ClinicalTrials.gov

Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

May 31, 2015

Study Completion Date

March 31, 2016

Conditions
Metastatic Colorectal Adenocarcinoma
Interventions
DRUG

LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified

DRUG

LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks

Trial Locations (1)

21079

CHU de Dijon, Dijon

All Listed Sponsors
lead

Centre Hospitalier Universitaire Dijon

OTHER

NCT01900717 - Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20) | Biotech Hunter | Biotech Hunter